Target Information
| Target General Information | Top | |||||
|---|---|---|---|---|---|---|
| Target ID |
T84457
|
|||||
| Target Name |
GABA(A) receptor (GABAR)
|
|||||
| Gene Name |
NO-GeName
|
|||||
| Target Type |
Successful target
|
[1] | ||||
| Disease | [+] 1 Target-related Diseases | + | ||||
| 1 | Epilepsy/seizure [ICD-11: 8A61-8A6Z] | |||||
| UniProt ID | ||||||
| Drugs and Modes of Action | Top | |||||
|---|---|---|---|---|---|---|
| Approved Drug(s) | [+] 1 Approved Drugs | + | ||||
| 1 | Ganaxolone | Drug Info | Approved | Epileptic seizures | [2] | |
| Clinical Trial Drug(s) | [+] 6 Clinical Trial Drugs | + | ||||
| 1 | OV101 | Drug Info | Phase 3 | Angelman syndrome | [3] | |
| 2 | PH94B NS | Drug Info | Phase 3 | Social anxiety disorder | [4] | |
| 3 | Padsevonil | Drug Info | Phase 2/3 | Epilepsy | [5] | |
| 4 | BTD-001 | Drug Info | Phase 2 | Narcolepsy | [6] | |
| 5 | Evt201 | Drug Info | Phase 2 | Sleep-wake disorder | [7] | |
| 6 | SAGE-324 | Drug Info | Phase 2 | Essential tremor or related tremors | [8] | |
| Mode of Action | [+] 4 Modes of Action | + | ||||
| Modulator | [+] 4 Modulator drugs | + | ||||
| 1 | Ganaxolone | Drug Info | [2] | |||
| 2 | PH94B NS | Drug Info | [4] | |||
| 3 | Evt201 | Drug Info | [11] | |||
| 4 | SAGE-324 | Drug Info | [1] | |||
| Agonist | [+] 1 Agonist drugs | + | ||||
| 1 | OV101 | Drug Info | [9] | |||
| Inhibitor | [+] 1 Inhibitor drugs | + | ||||
| 1 | Padsevonil | Drug Info | [10] | |||
| Antagonist | [+] 1 Antagonist drugs | + | ||||
| 1 | BTD-001 | Drug Info | [6] | |||
| References | Top | |||||
|---|---|---|---|---|---|---|
| REF 1 | Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. | |||||
| REF 2 | FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 215904. | |||||
| REF 3 | ClinicalTrials.gov (NCT03882918) An Open-Label Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of OV101 in Individuals With Angelman Syndrome. U.S.National Institutes of Health. | |||||
| REF 4 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||||
| REF 5 | ClinicalTrials.gov (NCT03370120) Study to Test the Safety and Efficacy of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adult Subjects With Drug-resistant Epilepsy. U.S. National Institutes of Health. | |||||
| REF 6 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||||
| REF 7 | ClinicalTrials.gov (NCT00380003) Efficacy Study of EVT 201 to Treat Insomnia. U.S. National Institutes of Health. | |||||
| REF 8 | ClinicalTrials.gov (NCT04305275) A Study to Evaluate the Efficacy, Safety, and Tolerability of SAGE-324 in Participants With Essential Tremor. U.S. National Institutes of Health. | |||||
| REF 9 | Gaboxadol in Fragile X Syndrome: A 12-Week Randomized, Double-Blind, Parallel-Group, Phase 2a Study. Front Pharmacol. 2021 Oct 8;12:757825. | |||||
| REF 10 | Pharmacological Profile of the Novel Antiepileptic Drug Candidate Padsevonil: Characterization in Rodent Seizure and Epilepsy Models. J Pharmacol Exp Ther. 2020 Jan;372(1):11-20. | |||||
| REF 11 | The partial positive allosteric GABA(A) receptor modulator EVT 201 is efficacious and safe in the treatment of adult primary insomnia patients. Sleep Med. 2009 Sep;10(8):859-64. | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.